Innovation - A robustness-based approach to systems-oriented drug design

被引:350
作者
Kitano, Hiroaki [1 ]
机构
[1] Sony Comp Sci Labs Inc, Shinagawa Ku, Tokyo 1410022, Japan
[2] Syst Biol Inst, Tokyo 1500001, Japan
[3] Inst Canc Res, Dept Canc Syst Biol, Koutou Ku, Tokyo 1358550, Japan
基金
日本科学技术振兴机构;
关键词
D O I
10.1038/nrd2195
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Many potential drugs that specifically target a particular protein considered to underlie a given disease have been found to be less effective than hoped, or to cause significant side effects. The intrinsic robustness of living systems against various perturbations is a key factor that prevents such compounds from being successful. By studying complex network systems and reformulating control and communication theories that are well established in engineering, a theoretical foundation for a systems-oriented approach to more effectively control the robustness of living systems, particularly at the cellular level, could be developed. Here, I use examples that are based on existing drugs to illustrate the concept of robustness, and then discuss how a greater consideration of the importance of robustness could influence the design of new drugs that will be intended to control complex systems.
引用
收藏
页码:202 / 210
页数:9
相关论文
共 102 条
  • [91] Scale-rich metabolic networks
    Tanaka, R
    [J]. PHYSICAL REVIEW LETTERS, 2005, 94 (16) : 1 - 4
  • [92] RAPID INVITRO SELECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RESISTANT TO 3'-THIACYTIDINE INHIBITORS DUE TO A MUTATION IN THE YMDD REGION OF REVERSE-TRANSCRIPTASE
    TISDALE, M
    KEMP, SD
    PARRY, NR
    LARDER, BA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (12) : 5653 - 5656
  • [93] Torrieri D., 2004, PRINCIPLES SPREAD SP
  • [94] Innovation -: Rescuing drug discovery:: in vivo systems pathology and systems pharmacology
    van der Greef, J
    McBurney, RN
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (12) : 961 - 967
  • [95] Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719
  • [96] Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials
    Voldborg, BR
    Damstrup, L
    Spang-Thomsen, M
    Poulsen, HS
    [J]. ANNALS OF ONCOLOGY, 1997, 8 (12) : 1197 - 1206
  • [97] Wakeling AE, 2002, CANCER RES, V62, P5749
  • [98] Lysogenic conversion by a filamentous phage encoding cholera toxin
    Waldor, MK
    Mekalanos, JJ
    [J]. SCIENCE, 1996, 272 (5270) : 1910 - 1914
  • [99] Metabolomics in the context of systems biology: Bridging traditional Chinese medicine and molecular pharmacology
    Wang, M
    Lamers, RJAN
    Korthout, HAAJ
    van Nesselrooij, JHJ
    Witkamp, RF
    van der Heijden, R
    Voshol, PJ
    Havekes, LM
    Verpoorte, R
    van der Greef, J
    [J]. PHYTOTHERAPY RESEARCH, 2005, 19 (03) : 173 - 182
  • [100] Traditional Chinese medicine: an approach to scientific proof and clinical validation
    Yuan, R
    Lin, Y
    [J]. PHARMACOLOGY & THERAPEUTICS, 2000, 86 (02) : 191 - 198